US FDA extends review timeline of Regenxbio’s BLA for clemidsogene lanparvovec to treat Mucopolysaccharidosis II: Rockville, Maryland Wednesday, August 20, 2025, 18:00 Hrs [IST] ...

REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) extended its review timeline of the Biologics License Application (BLA) for clemidsogene lanparvovec (RGX ...

The FDA has postponed its decision date for Regenxbio’s Hunter syndrome gene therapy to review additional longer-term ...

FDA extends the decision on Regenxbio's RGX-121 for Hunter syndrome to February 2026 following the submission of new ...

Regenxbio (RGNX) announced that the U.S. Food and Drug Administration extended its review timeline of the Biologics License Application for ...

Leerink analyst Mani Foroohar keeps an Outperform rating on Regenxbio (RGNX) after the company announced the FDA extended its review of ...

This phase 2b/3 trial follows new, positive 2-year data from the phase 2 ALTITUDE trial, in which sura-vec was well-tolerated ...

The US Food and Drug Administration (FDA) has extended Regenxbio’s review timeline of the Biologics License Application (BLA) ...

Analysts have recently evaluated Regenxbio and provided 12-month price targets. The average target is $38.4, accompanied by a high estimate of $52.00 and a low estimate of $17.00. Highlighting a 8.13% ...

From my colleague Allison DeAngelis: A new oral weight loss drug developed by Viking Therapeutics hit the mark in a mid-stage ...

Regenxbio is definitely a platform stock with much potential. I speculated that it will do very well in 2019 but surely, it is positive to performed well in the ultra long haul.

REGENXBIO earned a $3.5 million milestone payment upon Zolgensma's approval in the United States and is eligible to receive an additional $80 million milestone payment upon the achievement of $1 ...